Literature DB >> 29712507

Sulodexide Monotherapy in Chronic Idiopathic Subjective Tinnitus: A Randomized Controlled Trial.

Marc El Beaino1, Meghan K McCaskey2, Elie Eter1.   

Abstract

Objective To report the therapeutic value of sulodexide monotherapy in the management of patients with chronic subjective idiopathic tinnitus. Study Design Randomized double-blinded controlled trial. Setting Single tertiary care institution. Subjects and Methods Observations from 124 patients who received either sulodexide or placebo were collected from the patients' medical records. Computer-generated tables were used to allocate treatments. Patients took 1 tablet of the drug or placebo each morning and evening for 40 consecutive days. The response was assessed by the Tinnitus Handicap Inventory and the Mini-Tinnitus Questionnaire. Results Between 2014 and 2017, 124 patients were divided into 2 treatment arms. The sulodexide group encompassed 63 patients, whereas the placebo arm contained 61 patients. Tinnitus Handicap Inventory and Mini-Tinnitus Questionnaire scores were more decreased in the sulodexide arm compared to the placebo group ( P = .03 and P < .01, respectively). Conclusions Sulodexide monotherapy decreases chronic subjective idiopathic tinnitus.

Entities:  

Keywords:  Mini-Tinnitus Questionnaire; Tinnitus Handicap Inventory; anticoagulant; randomized controlled trial; sulodexide; tinnitus

Mesh:

Substances:

Year:  2018        PMID: 29712507     DOI: 10.1177/0194599818767618

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

Review 1.  Auditory Neural Plasticity in Tinnitus Mechanisms and Management.

Authors:  Kunkun Wang; Dongmei Tang; Jiaoyao Ma; Shan Sun
Journal:  Neural Plast       Date:  2020-07-01       Impact factor: 3.599

2.  Intervention of the Syndrome-Position Point Selection Method on Idiopathic Tinnitus of Phlegm-Fire Stagnation Pattern: A Randomized Controlled Study.

Authors:  Qiang Su; Xin Shi; Jianning Zhang; Ming Li
Journal:  J Healthc Eng       Date:  2022-03-23       Impact factor: 2.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.